Does the media refer more to SSII or EMBC?

In the previous week, Embecta had 25 more articles in the media than SS Innovations International. MarketBeat recorded 29 mentions for Embecta and 4 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 0.72 beat Embecta's score of 0.08 indicating that SS Innovations International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, BBNX or EMBC?

Embecta has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $100.25M 7.45 -$73.20M -$1.51 N/A Embecta $1.08B 0.18 $95.40M $1.90 1.76

Is BBNX or EMBC more profitable?

Embecta has a net margin of 10.73% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% Embecta 10.73% -23.96% 14.12%

Does the media refer more to BBNX or EMBC?

In the previous week, Embecta had 21 more articles in the media than Beta Bionics. MarketBeat recorded 29 mentions for Embecta and 8 mentions for Beta Bionics. Embecta's average media sentiment score of 0.08 beat Beta Bionics' score of -0.27 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 1 Very Positive mention(s) 0 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, CBLL or EMBC?

Embecta has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $95.07M 7.80 -$53.41M -$1.63 N/A Embecta $1.08B 0.18 $95.40M $1.90 1.76

Is CBLL or EMBC more profitable?

Embecta has a net margin of 10.73% compared to CeriBell's net margin of -63.51%. Embecta's return on equity of -23.96% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Embecta 10.73% -23.96% 14.12%

Does the media refer more to CBLL or EMBC?

In the previous week, Embecta had 22 more articles in the media than CeriBell. MarketBeat recorded 29 mentions for Embecta and 7 mentions for CeriBell. CeriBell's average media sentiment score of 0.10 beat Embecta's score of 0.08 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 1 Very Positive mention(s) 0 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SGP or EMBC?

In the previous week, Embecta had 28 more articles in the media than Spyglass Pharma. MarketBeat recorded 29 mentions for Embecta and 1 mentions for Spyglass Pharma. Embecta's average media sentiment score of 0.08 beat Spyglass Pharma's score of 0.00 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 1 Very Positive mention(s) 0 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, SIBN or EMBC?

Embecta has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $206.22M 3.68 -$18.90M -$0.39 N/A Embecta $1.08B 0.18 $95.40M $1.90 1.76

Is SIBN or EMBC more profitable?

Embecta has a net margin of 10.73% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Embecta 10.73% -23.96% 14.12%

Embecta (EMBC) Competitors

$3.35 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.35 +0.00 (+0.09%)

As of 07/2/2026 07:56 PM Eastern

Compare

EMBC vs. SSII, BBNX, CBLL, SGP, and SIBN

Should you buy Embecta stock or one of its competitors? MarketBeat compares Embecta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Embecta include SS Innovations International (SSII), Beta Bionics (BBNX), CeriBell (CBLL), Spyglass Pharma (SGP), and SiBone (SIBN). These companies are all part of the "medical equipment" industry.

How does Embecta compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Embecta (NASDAQ:EMBC) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

SS Innovations International has a beta of -1.96, meaning that its share price is 296% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

In the previous week, Embecta had 25 more articles in the media than SS Innovations International. MarketBeat recorded 29 mentions for Embecta and 4 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 0.72 beat Embecta's score of 0.08 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	17.80	-$12.13M	-$0.05	N/A
Embecta	$1.08B	0.18	$95.40M	$1.90	1.76

Embecta has a net margin of 10.73% compared to SS Innovations International's net margin of -20.69%. SS Innovations International's return on equity of -23.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Embecta	10.73%	-23.96%	14.12%

SS Innovations International presently has a consensus price target of $7.00, indicating a potential upside of 85.19%. Embecta has a consensus price target of $11.00, indicating a potential upside of 228.36%. Given Embecta's stronger consensus rating and higher possible upside, analysts plainly believe Embecta is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

93.8% of Embecta shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Embecta beats SS Innovations International on 12 of the 15 factors compared between the two stocks.

How does Embecta compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Beta Bionics has a beta of 3.04, indicating that its stock price is 204% more volatile than the broader market. Comparatively, Embecta has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Beta Bionics presently has a consensus price target of $19.70, suggesting a potential upside of 17.54%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 228.36%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

93.8% of Embecta shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Embecta had 21 more articles in the media than Beta Bionics. MarketBeat recorded 29 mentions for Embecta and 8 mentions for Beta Bionics. Embecta's average media sentiment score of 0.08 beat Beta Bionics' score of -0.27 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.45	-$73.20M	-$1.51	N/A
Embecta	$1.08B	0.18	$95.40M	$1.90	1.76

Embecta has a net margin of 10.73% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Embecta	10.73%	-23.96%	14.12%

Summary

Embecta beats Beta Bionics on 10 of the 17 factors compared between the two stocks.

How does Embecta compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

CeriBell has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, Embecta had 22 more articles in the media than CeriBell. MarketBeat recorded 29 mentions for Embecta and 7 mentions for CeriBell. CeriBell's average media sentiment score of 0.10 beat Embecta's score of 0.08 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$95.07M	7.80	-$53.41M	-$1.63	N/A
Embecta	$1.08B	0.18	$95.40M	$1.90	1.76

CeriBell presently has a consensus price target of $22.20, indicating a potential upside of 13.55%. Embecta has a consensus price target of $11.00, indicating a potential upside of 228.36%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

Embecta has a net margin of 10.73% compared to CeriBell's net margin of -63.51%. Embecta's return on equity of -23.96% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Embecta	10.73%	-23.96%	14.12%

93.8% of Embecta shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 1.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Embecta beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does Embecta compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Embecta (NASDAQ:EMBC) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Embecta has a net margin of 10.73% compared to Spyglass Pharma's net margin of 0.00%. Spyglass Pharma's return on equity of 0.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Embecta	10.73%	-23.96%	14.12%

Spyglass Pharma presently has a consensus target price of $45.00, indicating a potential upside of 134.99%. Embecta has a consensus target price of $11.00, indicating a potential upside of 228.36%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

93.8% of Embecta shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Embecta had 28 more articles in the media than Spyglass Pharma. MarketBeat recorded 29 mentions for Embecta and 1 mentions for Spyglass Pharma. Embecta's average media sentiment score of 0.08 beat Spyglass Pharma's score of 0.00 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Embecta has higher revenue and earnings than Spyglass Pharma. Spyglass Pharma is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
Embecta	$1.08B	0.18	$95.40M	$1.90	1.76

Summary

Embecta beats Spyglass Pharma on 10 of the 13 factors compared between the two stocks.

How does Embecta compare to SiBone?

SiBone (NASDAQ:SIBN) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, Embecta had 29 more articles in the media than SiBone. MarketBeat recorded 29 mentions for Embecta and 0 mentions for SiBone. Embecta's average media sentiment score of 0.08 beat SiBone's score of 0.00 indicating that Embecta is being referred to more favorably in the news media.

Company	Overall Sentiment
SiBone	Neutral
Embecta	Neutral

SiBone has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

98.1% of SiBone shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Embecta has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.68	-$18.90M	-$0.39	N/A
Embecta	$1.08B	0.18	$95.40M	$1.90	1.76

Embecta has a net margin of 10.73% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Embecta	10.73%	-23.96%	14.12%

SiBone currently has a consensus target price of $23.00, suggesting a potential upside of 34.42%. Embecta has a consensus target price of $11.00, suggesting a potential upside of 228.36%. Given Embecta's higher possible upside, analysts clearly believe Embecta is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

Summary

Embecta beats SiBone on 10 of the 16 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EMBC vs. The Competition

Export

Metric	Embecta	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$198.75M	$9.63B	$7.16B	$12.48B
Dividend Yield	1.19%	1.62%	2.66%	6.52%
P/E Ratio	1.76	27.84	28.02	24.70
Price / Sales	0.18	18.50	540.37	99.49
Price / Cash	0.84	114.69	49.26	57.09
Price / Book	-0.30	6.19	10.96	6.46
Net Income	$95.40M	$179.69M	$3.57B	$337.01M
7 Day Performance	-3.82%	3.82%	2.12%	1.69%
1 Month Performance	-0.89%	10.36%	5.25%	3.81%
1 Year Performance	-67.54%	14.53%	33.29%	23.90%

Embecta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EMBC Embecta	4.5456 of 5 stars	$3.35 flat	$11.00 +228.4%	-67.5%	$198.75M	$1.08B	1.76	1,850	Trending News Gap Up
SSII SS Innovations International	2.2591 of 5 stars	$3.73 +5.7%	$7.00 +87.7%	-29.2%	$746.69M	$48.47M	N/A	4	Positive News Gap Up
BBNX Beta Bionics	2.6165 of 5 stars	$16.55 -2.7%	$19.70 +19.1%	+24.0%	$737.28M	$110.24M	N/A	294
CBLL CeriBell	1.7201 of 5 stars	$19.35 -3.1%	$22.20 +14.7%	+3.3%	$732.01M	$89.06M	N/A	N/A	News Coverage Insider Trade
SGP Spyglass Pharma	1.817 of 5 stars	$21.74 +0.4%	$45.00 +107.0%	N/A	$728.00M	N/A	N/A	65	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EMBC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Embecta (EMBC) Competitors

EMBC vs. SSII, BBNX, CBLL, SGP, and SIBN

How does Embecta compare to SS Innovations International?

Summary

How does Embecta compare to Beta Bionics?

Summary

How does Embecta compare to CeriBell?

Summary

How does Embecta compare to Spyglass Pharma?

Summary

How does Embecta compare to SiBone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EMBC vs. The Competition

Embecta Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Embecta (EMBC) Competitors

EMBC vs. SSII, BBNX, CBLL, SGP, and SIBN

How does Embecta compare to SS Innovations International?

Which has more volatility & risk, SSII or EMBC?

Does the media refer more to SSII or EMBC?

Which has stronger valuation and earnings, SSII or EMBC?

Is SSII or EMBC more profitable?

Do analysts recommend SSII or EMBC?

Do insiders and institutionals have more ownership in SSII or EMBC?

Summary

How does Embecta compare to Beta Bionics?

Which has more volatility & risk, BBNX or EMBC?

Do analysts recommend BBNX or EMBC?

Do institutionals and insiders hold more shares of BBNX or EMBC?

Does the media refer more to BBNX or EMBC?

Which has stronger earnings & valuation, BBNX or EMBC?

Is BBNX or EMBC more profitable?

Summary

How does Embecta compare to CeriBell?

Which has more volatility & risk, CBLL or EMBC?

Does the media refer more to CBLL or EMBC?

Which has better earnings and valuation, CBLL or EMBC?

Do analysts rate CBLL or EMBC?

Is CBLL or EMBC more profitable?

Do insiders & institutionals believe in CBLL or EMBC?

Summary

How does Embecta compare to Spyglass Pharma?

Is SGP or EMBC more profitable?

Do analysts recommend SGP or EMBC?

Do insiders and institutionals believe in SGP or EMBC?

Does the media prefer SGP or EMBC?

Which has better valuation & earnings, SGP or EMBC?

Summary

How does Embecta compare to SiBone?

Does the media favor SIBN or EMBC?

Which has more risk & volatility, SIBN or EMBC?

Do institutionals & insiders hold more shares of SIBN or EMBC?

Which has better valuation and earnings, SIBN or EMBC?

Is SIBN or EMBC more profitable?

Do analysts rate SIBN or EMBC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EMBC vs. The Competition

Embecta Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools